Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor
RATIONALE: Studying samples of blood and tissue from newborns and from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies cord blood and placenta tissue from newborns, and tumor tissue samples from patients with Wilms tumor.
Genetic: DNA methylation analysis
Genetic: RNA analysis
Genetic: allele-specific oligonucleotide real-time quantitative polymerase chain reaction
Genetic: gene expression analysis
Genetic: nucleic acid sequencing
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Investigating the Frequency of Loss of Imprinting Across a Birth Cohort and the Link DNA Methylation Plays|
- Frequency of loss of imprinting at birth [ Designated as safety issue: No ]
- Association between methylation levels and gene expression [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
blood and tissue
|Study Start Date:||April 2012|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- What is the frequency of loss of imprinting at birth (in the cord blood and placenta) in a relatively healthy birth cohort?
- Does deoxyribonucleic acid (DNA) methylation levels at imprinting genes have a direct association to the gene expression?
OUTLINE: Archived tumor tissue, cord blood, and placenta samples are analyzed for DNA methylation, single nucleotide polymorphism, and gene expression by polymerase chain reaction (PCR), pyrosequencing, and quantitative real-time PCR. Information regarding gender and age of the samples are also collected, if possible.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01576211
|Principal Investigator:||Karin Michels, MD, PhD||Dana-Farber/Brigham and Women's Cancer Center|